ADMA Biologics
ADMA
74 hedge funds and large institutions have $130M invested in ADMA Biologics in 2019 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 32 increasing their positions, 15 reducing their positions, and 13 closing their positions.
113% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 15
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
3% more funds holding
Funds holding: 72 → 74 (+2)
7.96% less ownership
Funds ownership: 62.69% → 54.73% (-8%)
16% less call options, than puts
Call options by funds: $107K | Put options by funds: $128K
22% less capital invested
Capital invested by funds: $165M → $130M (-$35.6M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.6M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.35M |
| 3 |
Goldman Sachs
New York
|
+$981K |
| 4 |
State Street
Boston,
Massachusetts
|
+$641K |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$632K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$3.16M |
| 2 |
Millennium Management
New York
|
-$2.6M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$2.44M |
| 4 |
BC
Broadfin Capital
New York
|
-$2.25M |
| 5 |
JG
Jefferies Group
New York
|
-$2.23M |
ADMA Hedge Fund Activity: Q4 2019 in Review
74 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q4 2019, worth a combined $130M — down 22% from $165M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ADMA positions and 13 closed out — a net gain of 3 holders — while 32 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock, adding an estimated $3.6M. The largest seller was 683 Capital Management, cutting an estimated $3.16M.
- 74 institutional investors held ADMA Biologics (ADMA) as of Q4 2019, up from 72 in Q3 2019.
- Funds reported $130M of ADMA Biologics stock for Q4 2019, down 22% quarter-over-quarter.
- 16 funds opened new ADMA Biologics positions in Q4 2019 and 13 closed out, a net change of +3 holders.
- The largest ADMA Biologics buyer in Q4 2019 was BlackRock, an estimated $3.6M added.
- The largest ADMA Biologics seller in Q4 2019 was 683 Capital Management, an estimated $3.16M sold.
Based on aggregated 13F filings for Q4 2019.